Similar articles

• Transfusion associated malaria in endemic areas.

  Choudhury N, Jolly JG, Ganguly NK, Mahajan RC, Dube ML. Choudhury N, et al. Indian Pediatr. 1991 May;28(5):554-7. Indian Pediatr. 1991. PMID: 1752686 No abstract available.
• Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites.

  de Jong RM, Tebeje SK, Meerstein-Kessel L, Tadesse FG, Jore MM, Stone W, Bousema T. de Jong RM, et al. Immunol Rev. 2020 Jan;293(1):190-215. doi: 10.1111/imr.12828. Epub 2019 Dec 16. Immunol Rev. 2020. PMID: 31840844 Free PMC article. Review.
• Malaria vaccine: a current perspective.

  Sharma S, Pathak S. Sharma S, et al. J Vector Borne Dis. 2008 Mar;45(1):1-20. J Vector Borne Dis. 2008. PMID: 18399312 Review.
• The use of transgenic parasites in malaria vaccine research.

  Othman AS, Marin-Mogollon C, Salman AM, Franke-Fayard BM, Janse CJ, Khan SM. Othman AS, et al. Expert Rev Vaccines. 2017 Jul;16(7):1-13. doi: 10.1080/14760584.2017.1333426. Epub 2017 May 30. Expert Rev Vaccines. 2017. PMID: 28525963 Review.
• Persistent ICT malaria P.f/P.v panmalarial and HRP2 antigen reactivity after treatment of Plasmodium falciparum malaria is associated with gametocytemia and results in false-positive diagnoses of Plasmodium vivax in convalescence.

  Tjitra E, Suprianto S, McBroom J, Currie BJ, Anstey NM. Tjitra E, et al. J Clin Microbiol. 2001 Mar;39(3):1025-31. doi: 10.1128/JCM.39.3.1025-1031.2001. J Clin Microbiol. 2001. PMID: 11230422 Free PMC article.